Shares of global pharmaceutical company Eli Lilly (NYSE:LLY)
jumped 3.8% in the afternoon session after a major competitor, Novo Nordisk, announced that its experimental obesity drug failed to show it was as effective as Lilly's tirzepatide in a head-to-head clinical trial.
PayPal stock extends gains on reports that digital payments giant has attracted buyout interest. Here’s why a potential takeover would be bullish for PYPL shares.
CrowdStrike stock sinks further as Anthropic launches “Code Security” solution, triggering a new wave of selloff among cybersecurity names. But CRWD shares are worth buying on this dip.
